LLY
Eli Lilly and Company
LLY has the edge over OPK overall, supported by stronger fundamentals and stronger modeled upside.
OPK
OPKO Health, Inc.
OPK trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OPK Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
OPK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
OPK PE Valuation
OPK has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over OPK on the outlook, with more favorable earnings and revenue expectations.
OPK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect OPK's revenue and profitability to decline, with its earnings holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OPK on earnings quality, reporting a profit while its opponent remains loss making.
OPK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.19 | +$0.06 |
| Q2 2026 | -$0.09 | +$0.16 |
| Q1 2026 | -$0.27 | -$0.20 |
| Q4 2025 | -$0.30 | -$0.21 |
| Q3 2025 | -$0.25 | -$0.06 |
| Q2 2025 | -$0.25 | +$0.08 |
| Q1 2025 | -$0.07 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.16 |
OPK is still losing money, but far less than before: $0.19 per share over the past year, against $0.53 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over OPK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OPK on profitability, with a higher operating margin.
OPK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $65.4M | -57% |
| Q2 2026 | $163.6M | +4.3% |
| Q1 2026 | $124.2M | -17% |
| Q4 2025 | $148.5M | -19% |
| Q3 2025 | $151.7M | -13% |
| Q2 2025 | $156.8M | -14% |
| Q1 2025 | $150M | -14% |
| Q4 2024 | $183.6M | +1% |
OPK's revenue has slid since its 2021 peak: $65M last quarter, down 57% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -48% | -80 points |
| Q2 2026 | -4.3% | +34 points |
| Q1 2026 | -41% | +3.7 points |
| Q4 2025 | -26% | -7.8 points |
| Q3 2025 | 32% | +24 points |
| Q2 2025 | -38% | -4.4 points |
| Q1 2025 | -45% | -3.6 points |
| Q4 2024 | -18% | +20 points |
OPK's operating margin was −48% last quarter, down 80 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OPK on cash generation, producing positive trailing cash flow while its opponent burns cash.
OPK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.1M | -$1.3M |
| Q2 2026 | -$46.5M | +$40.2M |
| Q1 2026 | -$21.1M | +$16.6M |
| Q2 2025 | -$86.7M | -$53.1M |
| Q1 2025 | -$37.7M | +$2.3M |
| Q2 2024 | -$33.7M | -$27.3M |
| Q1 2024 | -$40M | -$14.3M |
| Q4 2023 | -$41.3M | -$3.4M |
OPK has burned cash in most quarters: −$135M over the past year, against −$196M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OPK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -8.8M shares |
| 1 year | -4.3% | -33.4M shares |
| 3 years | -0.7% | -5M shares |
| 5 years | +15% | +94.6M shares |
| Available history | +25% | +151M shares |
OPK has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10.6M |
| Q2 2026 | $13M |
| Q1 2026 | $4.8M |
| Q4 2025 | $13.5M |
| Q3 2025 | $15.3M |
| Q2 2025 | $18.3M |
| Q1 2025 | — |
| Q4 2024 | $16.5M |
OPK spent $42M buying back its own shares over the past year, down 16% from the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OPK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -7.2x | Net Cash |
| Q4 2021 | 0.7x | Very low |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.3x | Net Cash |
| Q1 2021 | -0.4x | Net Cash |
| Q4 2020 | 1.3x | Healthy |
OPK has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OPK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 74.7 | Neutral |
OPK's weekly RSI is 59 (neutral) and its Stochastic is 75 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OPK PE vs Healthcare Sector
| Metric | OPK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
OPK has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
OPK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.60 | 4.4% above |
| 20 week MA | $1.50 | 11% above |
| 50 week MA | $1.36 | 23% above |
| 100 week MA | $1.40 | 19% above |
| 200 week MA | $1.42 | 18% above |
OPK has climbed back above all five of its weekly moving averages, and it's now 18% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OPK on returns for 2026, with the stronger performance.
OPK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.50 | $4.23 | +182% |
| 2021 | $4.23 | $4.77 | +13% |
| 2022 | $4.77 | $1.14 | -76% |
| 2023 | $1.14 | $1.51 | +32% |
| 2024 | $1.51 | $1.48 | -2% |
| 2025 | $1.48 | $1.29 | -13% |
| 2026 YTD | $1.29 | $1.67 | +29% |
OPK's yearly returns have swung widely, from +182% in 2020 to −76% in 2022. It's up 29% so far in 2026.